Stratec Se (SBS.DE) stock: key figures, P/E, revenue and dividend
Health Care · Germany · ISIN DE000STRA555
Stratec Se financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 257.00 m EUR | 250.00 m EUR |
| Gross profit | 76.00 m EUR | 64.00 m EUR |
| Operating income | 26.89 m EUR | 16.61 m EUR |
| EBIT | 28.00 m EUR | 8.00 m EUR |
| Net income | 16.00 m EUR | 0.00 EUR |
| Diluted EPS – continuing operations | 1.32 EUR | -0.02 EUR |
Full history since 1998, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Stratec Se
Stratec SE, together with its subsidiaries, provides automation solutions for in-vitro diagnostics and life science companies in Germany, the European Union, and internationally. The company designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers. It also provides consumables for diagnostics and medical applications; and instrumentation and software. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
More stocks
- Ningbo Lehui International Engineering Equipment Co Ltd Class A (603076.SS)
- COMNAV ORD A (SHH) EQSW Exp: (688592.SS)
- Test Rite International Co Ltd (2908.TW)
- Securetech Innovations, Inc. (SCTH)
- Dezhou United Petroleum Technology Co.Ltd. (301158.SZ)
- Gaumont SA (GAM.PA)
- SFC Energy (F3C.DE)
- Foresee Pharmaceuticals Co Ltd (6576.TWO)
- Focus Minerals Ltd (FML.AX)
- Dear U Co. Ltd. (376300.KQ)
- Shaanxi Meibang Pharmaceutical Group Co Ltd (605033.SS)
- AP Biosciences Inc (6945.TWO)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.